Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-131 vs Darbepoetin alfa in renal anemia with CKD
NCT02912494Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa biosimilar JR-131 in anemia of chronic kidney disease (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in Hemoglobin level at 24 weeks. Started Sep 2016; status: completed.
02
Drugs
darbepoetin alfa biosimilar JR-131
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT02912494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912494.